Barclays lowered the firm’s price target on Sarepta (SRPT) to $89 from $209 and keeps an Overweight rating on the shares. The company reported a Q1 miss and Elevidys revenue guidance was lowered by $500M-$600M, the analyst tells investors in a research note. The firm says that while Sarepta’s FDA uncertainty persists, it remains constructive on the shares long-term.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Therapeutics: Buy Rating Affirmed Amid Challenges and Recovery Prospects
- Sarepta Therapeutics Reports Revenue Growth Amid Losses
- Closing Bell Movers: Sarepta falls 21% after earnings and guidance cut
- Sarepta reports Q1 adjusted EPS ($3.42) vs 72c last year
- Sarepta cuts FY25 product revenue view to $2.3B-$2.6B from $2.9B-$3.1B